Correlation between MIB-1 staining index and the immunoreactivity of p53 protein in recurrent and non-recurrent meningiomas

American Journal of Clinical Pathology

Volumn 106, Issue 6, 1996, Pages 776-781

  Matsuno, Akira ^a   Nagashima, Tadashi ^a   Matsuura, Reiko ^b   Tanaka, Hideki ^a   Hirakawa, Makoto ^a   Murakami, Mineko ^a   Tamura, Akira ^c   Kirino, Takaaki ^b  

^a TEIKYO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c TEIKYO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Meningioma; MIB 1; p53 protein; Proliferative potential; Recurrence

Indexed keywords

PROTEIN P53;

ARTICLE; CELL PROLIFERATION; CORRELATION FUNCTION; DIAGNOSTIC VALUE; GROWTH REGULATION; HUMAN; HUMAN TISSUE; IMMUNOREACTIVITY; MENINGIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER;

EID: 0030474705     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/106.6.776     Document Type: Article

References (26)

1. Bagni A, Botticelli A, Martinelli A, Azzoni P, Trentini GP. Ag-NOR counts in recurrent and non-recurrent meningiomas. Histopathology 1991;19:465-467.
2. Chin LS, Hinton DR. The standardized assessment of argyrophilic nucleolar organizer regions in meningiomas. J Neurosurg 1991;74:590-596.
3. Gerdes J, Lemke H, Baisch H, et al., Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 1984;133:1710-1715.
4. Hoshino T, Nagashima T, Murovic JA, Wilson CB, Davis RL. Proliferative potential of human meningiomas of brain. Cancer 1986;58:1466-1472.
5. Karamitopoulou E, Perentes E, Diamantis I. p53 protein expression in central nervous system tumors: An immunohistochemical study with CM 1 polyvalent and DO-7 monoclonal antibodies. Acta Neuropathol 1993;85:611-616.
6. Karamitopoulou E, Perentes E, Diamantis I, Maraziotis T. Ki-67 immunoreactivity in human central nervous system neoplasms: A study with MIB1 monoclonal antibody on archival material. Acta Neuropathol 1994;87:47-54.
7. Ohta M, Iwaki T, Kitamoto T, et al. MIB1 staining index and scoring of histologic features in meningiomas: Indicators for the prediction of biologic potential and proliferative management. Cancer 1994;74:3176-3189.
8. Orita T, Kajiwara K, Nishizaki T, et al. Nucleolar organizer regions in meningioma. Neurosurgery 1990;26:43-46.
9. Paulus W, Meixensberger J, Hofmann E, Roggendorf W. Effect of embolisation of meningioma on Ki-67 proliferation index. J Clin Pathol 1993;46:876-877.
10. Shibuya M, Hoshino T, Ito S, et al. Meningiomas: Clinical implications of a high proliferative potential determined by bromodeoxyuridine labeling. Neurosurgery 1992;30:494-498.
11. Matsuno A, Fujimaki T, Sasaki T, et al. Clinical and histopathological analysis on proliferative potentials of recurrent and non-recurrent meningiomas. Acta Neuropathol 1996;91:504-510.
12. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB1 and MIB3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
13. Xiong Y, Hannon GJ, Zhang H, et al. p21 is a universal inhibitor of cyclin kinases. Nature 1993;366:701-704.
14. Chowdary DR, Dermody JJ, JHA KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994;14:1997-2003.
15. Zambetti GP, Levine AJ. A Comparison of the biological activities of wild-type and mutant p53. FASEB J 1993;7:855-865.
16. Gronostajski RM, Goldberg AJ, Pardee AB. Energy requirement for degradation of tumor-associated protein p53. Mol Cell Biol 1984;4:442-448.
17. Shibuya M, Utsunomiya H, Osamura RY. Identification of cells in proliferative phases using MIB-1 immunohistochemical method: Antigen retrieval in paraffin sections. Pathology and Clinical Medicine 1993;11:373-377 (in Japanese).
18. Shibuya M, Ito S, Miwa T, et al. Proliferative potential of brain tumors. Analyses with Ki-67 and anti-DNA polymerase alpha monoclonal antibodies, bromodeoxyuridine labeling, and nuclear organizer region counts. Cancer 1993;71:199-206.
19. Kleihues P, Burger PC, Scheithauer BW. The new WHO classification of brain tumors. Brain Pathol 1993;3:255-268.
20. Frankel RH, Bayona W, Koslow M, Newcomb EW. p53 mutations in human malignant gliomas: Comparison of loss of heterozygosity with mutation frequency. Cancer Res 1992;52:1427-1433.
21. Fulls D, Brockmeyer D, Tullous MW, Pedone CA, Cawthon RM. p53 mutation and loss of heterozygosity on chromosomes 17 and 10 during human astrocytoma progression. Cancer Res 1992;52:674-679.
22. Ohgaki H, Eibl RH, Schwab M, et al. Mutations of the p53 tumor suppressor gene in neoplasms of the human nervous system. Mol Carcinog 1993;8:74-80.
23. Mayashima S, Murakami Y, Yoshimoto T, Sekiya T, Hayashi K. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. Oncogene 1991;6:1313-1318.
24. Lekanne Deprez RH, Bianchi AB, et al. Frequent NF2 gene transcript mutations in sporadic meningiomas and vestibular schwannomas. Am J Hum Genet 1994;54:1022-1029.
25. Lindblom A, Ruttledge M, Collins VP, Nordenskjöld M, Dumanski JP. Chromosomal deletions in anaplastic meningiomas suggest multiple regions outside chromosome 22 as important in tumor progression. Int J Cancer 1994;56:354-357.
26. Rempel SA, Schwechheimer K, Davis RL. Cavenee WK, Rosenblum ML. Loss of heterozygosity for loci on chromosome 10 is associated with morphologically malignant meningioma progression. Cancer Res 1993;53:2386-2392.